Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
PMID: 28453836
2017
The Journal of infectious diseases
Abstract: At least 1 thymidine-analogue mutations was present in 2.7% of patients with 0.07% harboring T215Y/F and 2.7% harboring T215 revertant mutations (T215rev).
Use of Proviral DNA to Investigate Virus Resistance Mutations in HIV-infected Zimbabweans.
Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.
PMID: 28659324
2017
Journal of clinical microbiology
Abstract: ART-naive HIV-1-infected patients from Cameroon were subjected to a multimethod HIVDR analysis using amplification-refractory mutation system (ARMS)-PCR, Sanger sequencing, and longitudinal next-generation sequencing (NGS) to determine their profiles for the mutations K103N, Y181C, K65R, M184V, and T215F/Y.
Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.
Abstract: Overall, 32% (37/116) patients presented >= one major drug resistant mutation(s), with 29% (34/116) to nucleos(t)ide reverse transcriptase inhibitors (67% [29/43] M184V/I, 30% [13/43] T215Y/F, 19% [8/43] V75A/F/I/L/M, 9% [4/43] K70P/R/W, 9% [4/43] Result: Out of the 43 sequences generated, the most prevalent DRMs were: (67% [29/43] M184V/I, 30% [13/43] T215Y/F, 19% [8/43] V75A/F/I/L/M, 9% [4/43] K70P/R/W, 9% [4/43] K219E/N/Q and 5% [2/43] A62V, followed by other DRMs observed at low rates.
Characterization of Nucleoside Reverse Transcriptase Inhibitor-Associated Mutations in the RNase H Region of HIV-1 Subtype C Infected Individuals.
Result: The most frequently observed reverse transcriptase (RT) drug resistance mutations in NRTI-experienced patients were M184I/V (64.2%), D67N (25.9%), K70R (19.6%), K219Q/E (17.9%) and T215Y/F (13.4%).
Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaounde, Cameroon.
Abstract: Overall, 7.3% transmitted and 34.3% acquired DRMs were found, including M184V, thymidine analogue mutations (T215F, D67N, K70R, K219Q), NNRTIs (L100I, Y181C, K103N, V108I, Y188L), and PIs (V82L).
Table: T215F
Discussion: In addition to the resistance mutations to NRTIs (M184V and the TAM T215F) and NNRTIs (L
Antiretroviral Drug Resistance Mutations among HIV Treatment Failure Patients in Tehran, Iran.
PMID: 29026792
2017
Iranian journal of public health
Abstract: The analysis of reverse transcriptase showed M184V (68.9%), T215YISF (44.8%), K103N (27.6%) and the analysis results of protease revealed G73SC (13.8%) and I47VA (6.9%).
High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.
Result: Interestingly, among the viruses with mutations at this position, tyrosine (Y) was the dominant amino acid (6.9%; T215Y) compared to the complete absence of phenylalanine (F) (0%; T215F.
Result: TAMs were dominated by D67N (13.8%), followed by K219Q/E (12.1%) and K70R (12.1%) with a low occurrence of T215Y/F (6.9%).
Result: The 215I mutation seems to be transitional (intermediate) to T215F (phenylalanine-TTT, TTC).
Result: The T215Y/F mutation seem to be subtype specific as it was recently found as the dominant TAM in 33.6% of non-subtype C infected study subjects in five Central African countries.
HIV mutation literature information.
PMID: 
2017
The Journal of infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT